Quarterly report pursuant to Section 13 or 15(d)

Segments (Tables)

Segments (Tables)

3 Months Ended

Mar. 31, 2015

Schedule of segment reporting information

The information in the following table is derived directly from each reportable segment’s financial reporting.



($ amounts in thousands) Three Months Ended March 31, 2015	Diagnostics			Therapeutics			Corporate			Total
Lymphoseek sales revenue:
United States¹	$	1,831		$	—		$	—		$	1,831
International	6			—			—			6
Lymphoseek license revenue	83			—			—			83
Grant and other revenue	190			—			—			190
Total revenue	2,108			—			—			2,108
Research and development expenses	3,895			86			—			3,981
Selling, general and administrative expenses, excluding depreciation and amortization²	2,042			14			3,324			5,380
Depreciation and amortization	72			—			78			150
Loss from operations³	(4,315		)	(100		)	(3,401		)	(7,816		)
Other income (expense), excluding equity in the loss of R-NAV, LLC⁴	—			—			787			787
Equity in the loss of R-NAV, LLC	—			—			(262		)	(262		)
Loss attributable to common stockholders	(4,315		)	(146		)	(2,876		)	(7,337		)
Total assets, net of depreciation and amortization:
United States	3,334			7			7,078			10,419
International	496			—			3			499
Capital expenditures	—			—			—			—

¹All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies.

²General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.

³ Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

⁴ Amounts consist primarily of interest income, interest expense and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details